Intended for use in patients with viral loads ≥500 copies/mL. HIV-1 combined pheno- and genotyping test to provide antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (ie, NRTI and NNRTI), and integrase inhibitors (INI). Preferred test for patients with known or suspected complex drug resistance patterns (eg, suboptimal virologic response to treatment and viral load rebound).
Polymerase Chain Reaction (PCR)/Culture
New York DOH Approval Status
Lavender (EDTA) or plasma preparation tube (PPT).
Separate from cells within 6 hours of collection. Transfer 5 mL plasma to ARUP Standard Transport Tubes and freeze immediately. (Min: 3 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 2 weeks
Performed by non-ARUP Laboratory
Procedure should be used for patients with documented HIV-1 infection and viral loads greater than 500 copies/mL.
87900; 87901; 87903; 87904 x16; 87906
|Component Test Code*||Component Chart Name||LOINC|
|3001187||EER HIV-1 PhenoSense GT + Integrase||51969-4|
|3001188||HIV-1 PSGT + Integrase, Net Assessment||83326-9|
|3001189||HIV-1 PSGT + Integrase, Phenotype||49665-3|
|3001190||HIV-1 PSGT + Integrase, Genotype|
|3001191||HIV-1 PSGT + Integrase, Interpretation||77202-0|